Drug intelligence / Profile preview

pd5k3

Development stage: Phase 1
Lead developer: Chongqing Paijin Biotechnology
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

PD5K3 is an investigational drug currently in clinical trials for evaluation of safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy adult volunteers. It is being compared to pegaspargase at the same dose. The primary aim of these studies is to assess whether PD5K3 is safe and active in humans. The drug appears to be a pegylated recombinant asparaginase or a related enzyme-based therapy based on its comparison with pegaspargase[1][3][5].

Targets

ASNS (Aspartate-ammonia ligase)

Beyond the preview

Go deeper on pd5k3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pd5k3.

Explore the full profile